NIDCR

RevBio Awarded a $2 Million Follow-On NIH Grant to Reduce Opioid Use and Addiction with TETRANITE®

Retrieved on: 
Wednesday, October 25, 2023
Other Health, Research, Pharmaceutical, Medical Devices, Dental, Clinical Trials, Science, Biotechnology, Medical Supplies, FDA, Other Science, Health, NIDCR, Extraction (chemistry), MMSc, Alveolar osteitis, SBIR, Doctor of Philosophy, United, Multimedia, OUD, Tissue, Phase II, DRS, Tooth, NIH, United States drug overdose death rates and totals over time, Initiative, DMD, Regenerative medicine, Pain management, Addiction, Pain, Patient, Diagnosis, Bangladesh Technical Education Board, Pharmaceutical industry, Dentistry, Medical device

This product is intended to be used to fill extraction sites and mitigate post-operative pain following the removal of wisdom teeth.

Key Points: 
  • This product is intended to be used to fill extraction sites and mitigate post-operative pain following the removal of wisdom teeth.
  • This grant will fund the pre-clinical development of a dental bone graft formulation that will include the release of locally acting non-opioid pain medication.
  • Opioid use disorder (OUD) is a major problem in the US, accounting for 107,622 overdose deaths in 2021.
  • This also expands upon a Phase II SBIR grant ( 1R44DE032564-01 ) which RevBio received from the National Institute of Dental and Cranial Research (NIDCR).

RevBio is Awarded a $2 Million Grant to Advance the Development of its Novel Dental Adhesive Bone Scaffold Product

Retrieved on: 
Wednesday, June 7, 2023
Health, Medical Devices, Dental, Clinical Trials, Research, Science, Biotechnology, Maintenance, Extraction (chemistry), Surgeon, University, Osteoporosis, Tooth, SBIR, University of Pennsylvania School of Dental Medicine, Porosity, Multimedia, Doctor of Philosophy, Bangladesh Technical Education Board, Regenerative medicine, National Institute of Dental and Craniofacial Research, Membrane, DMD, Patient, NIDCR, Engineering, Dentistry, IDE, FDA, All India Mahila Congress, NIH, Safety

This funding ( 1R44DE032564-01 ) will allow the company to complete the pre-clinical research necessary to advance this product into the clinical stage of development.

Key Points: 
  • This funding ( 1R44DE032564-01 ) will allow the company to complete the pre-clinical research necessary to advance this product into the clinical stage of development.
  • These products do not predictably maintain ridge volume which requires surgeons to undergo re-grafting in over 30% of clinical cases.
  • These procedures increase the width and height of the residual jawbone to replace atrophied bone so that a dental implant can be successfully placed.
  • This product compliments RevBio’s existing clinical program to treat the larger population of patients who need an immediate dental implant following tooth extraction.

Amend Surgical Receives Funding for Suture-less Nerve Repair Device

Retrieved on: 
Tuesday, April 11, 2023
SpaceTEC National Resource Center for Aerospace Technical Education, Tissue, Partnership, Commercialization, Connective tissue, University, Nerve, Marketing, Harvard University, Elective surgery, ITP, Spine, DOC, Research, Private practice, Sympathetic nervous system, Bangladesh Technical Education Board, Regenerative medicine, National Institute of Dental and Craniofacial Research, Regeneration, Motion, Wyss Institute, NIDCR, Collagen, OEM, FDA, Trauma, Wyss Institute for Biologically Inspired Engineering, Pharmaceutical industry, Dentistry

ALACHUA, Fla., April 11, 2023 /PRNewswire/ -- Amend Surgical, Inc., an Alachua-based medical device company, announced today that it has been awarded a substantial product development funding from The Michigan-Pittsburgh-Wyss Regenerative Medicine (MPWRM) Resource Center to commercialize a novel, suture-less solution for the repair of peripheral nerves. Tissure is a resorbable hydrogel membrane with a chitosan-based adhesive that has the adhesion and mechanical strength to potentially replace suture for the repair of peripheral nerve injuries. Tissure is easy to apply and will greatly simplify this challenging surgical procedure. Amend Surgical exclusively licensed the rights for this technology from the Wyss Institute at Harvard University in 2020.

Key Points: 
  • Amend Surgical exclusively licensed the rights for this technology from the Wyss Institute at Harvard University in 2020.
  • The use of suture to repair peripheral nerve injuries is the current standard of care.
  • Eliminating suture for peripheral nerve repair avoids this trauma, can decrease intervening scar tissue, and protect the repair site.
  • Amend Surgical currently has nine employees and occupies a manufacturing and administrative space in the biotech corridor of Alachua, Florida.

Oak Dental Partners Selects VideaHealth as AI Partner to Elevate Patient Care and Experience

Retrieved on: 
Thursday, March 23, 2023
Other Health, Software, Internet, Data Management, Consumer Electronics, Technology, Artificial Intelligence, Health Technology, Dental, Audio, Video, Other Technology, Health, Dentistry, Workflow, Parent, Statistics, Radioactive decay, DSO, CDC, Dentist, Tooth decay, Trust, DMD, Patient, ODP, NIDCR, Ethics, Ageing, AI, FDA, Family, Conditional sentence, Disease, Medical device

Oak Dental Partners (ODP), a leading family and pediatric dental service organization (DSO), has selected VideaHealth , the trusted dental AI provider, as its AI partner of choice.

Key Points: 
  • Oak Dental Partners (ODP), a leading family and pediatric dental service organization (DSO), has selected VideaHealth , the trusted dental AI provider, as its AI partner of choice.
  • This seamlessly enhances diagnostic recommendations so clinicians can deliver better patient outcomes and experiences.
  • As a pediatric provider, I want to have every parent involved in terms of what's going on with their child's health,” said Deep Shah, DMD, Oak Dental Partners.
  • “Oak Dental Partners invests heavily in its affiliated dentists so they can focus on delivering exceptional patient care.

Sinopia Awarded Grant from National Institute of Dental and Craniofacial Research for Oral Mucositis

Retrieved on: 
Thursday, February 23, 2023
Technology, Biotechnology, FDA, Health, Radiology, Oncology, Other Science, Research, Software, General Health, Health Technology, Science, Data Management, Clinical Trials, Discover, Overalls, National Institute of Dental and Craniofacial Research, Prognosis, Patient, Inflammation, Learning health systems, Therapy, Ulcer, Machine learning, Head, Bangladesh Technical Education Board, Radiation, NIDCR, Pharmaceutical industry, Dentistry, Mucositis

Sinopia Biosciences, Inc. , a biotechnology company advancing novel therapeutics identified using its proprietary computational drug discovery platform, has been awarded a grant from the National Institute of Dental and Craniofacial Research (NIDCR), a branch of the U.S. National Institutes of Health, to fund the continued evaluation of therapeutic candidates to treat oral mucositis.

Key Points: 
  • Sinopia Biosciences, Inc. , a biotechnology company advancing novel therapeutics identified using its proprietary computational drug discovery platform, has been awarded a grant from the National Institute of Dental and Craniofacial Research (NIDCR), a branch of the U.S. National Institutes of Health, to fund the continued evaluation of therapeutic candidates to treat oral mucositis.
  • Mucositis is a debilitating side effect of chemotherapy and radiotherapy that is characterized by inflammation and ulceration in mucosal tissue.
  • “When mucositis presents itself in cancer clinical care, there can be a delay in antineoplastic treatment for high-grade mucositis management that can lead to worse overall prognosis and significantly higher healthcare costs.
  • The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Kovina Therapeutics Receives NIH Grant to Develop Human Papillomavirus E6 Inhibitors to Treat Oropharyngeal Cancers

Retrieved on: 
Tuesday, November 1, 2022
Health, Infectious Diseases, Research, Pharmaceutical, Science, Biotechnology, Survival, CEO, Human papillomavirus infection, HPV-positive oropharyngeal cancer, Research, National Institute of Dental and Craniofacial Research, National Institute, NIH, Disease, Head, HPV, Oropharyngeal cancer, Incidence, NIDCR, Cancer, Therapy, Profile, SBIR, CSO, Biotechnology, Science, Small Business Innovation Research, Pharmaceutical industry, Vaccine

Kovina Therapeutics Inc. announced receipt of a Small Business Innovation Research (SBIR) one-year Phase I award from the National Institute of Dental and Craniofacial Research (NIDCR/NIH) to treat oropharyngeal cancers caused by Human Papillomavirus (HPV) infections.

Key Points: 
  • Kovina Therapeutics Inc. announced receipt of a Small Business Innovation Research (SBIR) one-year Phase I award from the National Institute of Dental and Craniofacial Research (NIDCR/NIH) to treat oropharyngeal cancers caused by Human Papillomavirus (HPV) infections.
  • Oropharyngeal cancers arising from HPV infections are increasing across many age groups and around the world.
  • This SBIR grant funds testing of our novel HPV inhibitory compounds for activity in preclinical models of oropharyngeal cancer.
  • Kovina Therapeutics is a biotechnology company developing first-in-class antiviral therapies to treat cancers and premalignant infections caused by Human Papillomavirus (HPV).

Penn Dental Medicine Study Finds Cavity-Causing Microbes Form Superorganism that Crawls on Teeth

Retrieved on: 
Tuesday, November 1, 2022
Tooth decay, Saliva, Fungus, Tooth, Dentistry, Science, Center, Partnership, Plaque, Bacteria, Disease, Innovation, National academy, Behavior, University of Pennsylvania School of Dental Medicine, University, NIDCR, National, Microscopy, Paper

PHILADELPHIA, Nov. 1, 2022 /PRNewswire/ -- A cross-kingdom partnership between bacteria and fungi can result in the two joining to form a "superorganism" with unusual strength and resilience.

Key Points: 
  • PHILADELPHIA, Nov. 1, 2022 /PRNewswire/ -- A cross-kingdom partnership between bacteria and fungi can result in the two joining to form a "superorganism" with unusual strength and resilience.
  • It may sound like science fiction, but these microbial groupings are very much part of the here and now.
  • Found in the saliva of toddlers with severe childhood tooth decay, these assemblages can effectively colonize teeth.
  • They were stickier, more resistant to antimicrobials, and more difficult to remove from teeth than either the bacteria or the fungi alone, according to a research team led by University of Pennsylvania School of Dental Medicine scientists.

TOMI Environmental Receives Order From National Institutes of Health (NIH); TOMI Products Now Deployed in Over 20 NIH Facilities Across 11 Divisions

Retrieved on: 
Thursday, October 20, 2022
Hydrogen, National Institute, U.S. Department of Defense Strategy for Operating in Cyberspace, NIEHS, Hydrogen peroxide, SEC, Government, Corrosion, Infection, VRC, IHP, National Institute of Dental and Craniofacial Research, Biosafety, NASDAQ, Annual report, COO, Restaurant, Decontamination, Hospital, Vaccine Research Center, HHS, Research, NIH, NIAID, DARPA, Police, National Institute of Environmental Health Sciences, Technology, Allergy, National Cancer Institute, RML, Rocky Mountain Laboratories, Disinfectant, Association, GLOBE, Office of Inspector General, U.S. Department of Health and Human Services, EPA, Forward-looking statement, COVID-19, NIDCR, Meat, School, NCI, Pharmaceutical industry

This purchase order reflects their continued implementation of SteraMist iHP technology within decontamination protocols to improve sterility and facility productivity.

Key Points: 
  • This purchase order reflects their continued implementation of SteraMist iHP technology within decontamination protocols to improve sterility and facility productivity.
  • In total, NIH has deployed approximately thirty (30) SteraMist machines across eleven (11) divisions, including National Institute of Allergy & Infectious Diseases (NIAID), National Institute of Environmental Health Sciences (NIEHS), National Institute of Dental and Craniofacial Research (NIDCR), National Cancer Institute (NCI), Vaccine Research Center (VRC), and Rocky Mountain Laboratories (RML).
  • Shane, COO of TOMI, states, SteraMist is used throughout many government agencies, and we take pride in supporting customers like NIH.
  • These forward-looking statements include, without limitation, statements relating to TOMIs ability to develop products for NIH and government use.

JDE Joins Other Dental Journals in Coordinated Focus on Oral Health in America

Retrieved on: 
Wednesday, May 25, 2022
Other Communications, Dental, Communications, Other Health, Other Education, Health, University, General Health, Education, NIDCR, Education, Knowledge, Dentistry, American Dental Association, Journal, Journal of Dental Research, National Institute, Patient, Pain management, Goal, National Institute of Dental and Craniofacial Research, Health, American Association of Public Health Dentistry, Thought, Research, Awareness, Journal of the American Dental Association, Student, Technology, School, National, Curriculum, ADEA, Health information management, JDE, Publishing, Pharmaceutical industry, Dental

In the JDE review article Oral health in America 2021: Making a case for curricular change, the authors call on dental schools to provide research training opportunities and recruit students who are interested in research.

Key Points: 
  • In the JDE review article Oral health in America 2021: Making a case for curricular change, the authors call on dental schools to provide research training opportunities and recruit students who are interested in research.
  • ADEA President and CEO Karen P. West, D.M.D., M.P.H., stressed the fundamental role of dental education in improving oral health.
  • The other journals publishing perspective papers and editorials about the oral health report are Journal of Dental Research, Journal of Public Health Dentistry and Journal of the American Dental Association.
  • The Oral Health in America report showed that although some measures of oral health have improved over the last 20 years, there is still much work to be done, said Dr. DSouza.

Renowned Dentist Dr Vikaskumar N. Patel Inducted Into Fellowship At The Prestigious PFA

Retrieved on: 
Friday, May 13, 2022
NIDCR, Fellow, MBA, American Academy, Pierre, Margaret, Photography, International Congress of Oral Implantologists, Rajarajeswari Dental college and Hospital, Academy, DDS, National Institute, Patient, New York Academy of Medicine, Sigma Beta Delta, Pierre Fauchard Academy, National Institute of Dental and Craniofacial Research, Learning, NYU, Dental surgery, Monroe College, Research, Industry, University, Ministry of Education (Malaysia), Organization, Dentistry, Love, Lists of schools in England, Medicine

COLUMBIA, Md., May 13, 2022 /PRNewswire-PRWeb/ -- The Pierre Fauchard Academy, founded in 1936, is an honorary dental service aimed to recognize and honor outstanding international leadership in the dental profession. Fellowship in the Academy is by nomination only. It is designed to celebrate past accomplishments in dentistry and encourage future productivity.

Key Points: 
  • Hot off the heels of his last fellowship, extraordinary Dentist Dr.Vikaskumar N. Patel is now a fellow of the prominent Pierre Fauchard Academy,an International Honor Dental Organization.
  • Today, the Pierre Fauchard Academy continues to house a distinguished cadre of dental experts and professionals from around the globe.
  • It is no surprise that such an illustrious organization has included Dr. Vikaskumar N. Patel in its ranks.
  • Dr. Patel was an honor student, finally graduating with the prestigious Sigma Beta Delta award.